Skip to content

Who We Are
- Leadership
- Our Culture
Careers
Contact Us

Our Science
Our Medicines
Medical Professionals
- Overview
- HCP Resources
Patients & Advocacy
Investors & Media

Our Science
Our Medicines
Medical Professionals
- Overview
- HCP Resources
Patients & Advocacy
Investors & Media
Who We Are
- Leadership
- Our Culture
Careers
Contact

Initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP201: A phase 2 study of avutometinib ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC)

Initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP201: A phase 2 study of avutometinib ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC)

Initial efficacy and safety results

Terms of Use
Compliance & Ethics
Copyright Statement
Privacy Policy
Contact
Sitemap

Twitter
Linkedin

© 2025 Verastem, Inc. All Rights Reserved.

This website uses cookies to improve the site and user experience. By continuing to browse this site, you agree to accept our use of cookies. For more information, please review our Privacy Policy.